Answers are grounded in this paper and cite their sources.
Objectives Oral nicotine pouches (ONPs) are tobacco-free products placed between the lip and gum to deliver nicotine. Sales have grown rapidly in the United States (U.S.), yet independent data on how nicotine characteristics shape ONP appeal and addiction potential are lacking. Three nicotine characteristics vary across ONPs: concentration (mass of nicotine per pouch), form (the fraction of freebase, or unprotonated, nicotine), and stereoisomer (the proportion of S- to R-nicotine). This study will determine how these characteristics independently and jointly affect ONP nicotine pharmacokinetics and user experience among adults who smoke cigarettes or use moist snuff . Design and participants This randomized, double-blind, crossover trial will enroll 160 adults who smoke cigarettes or use moist snuff at a single U.S. site. Interventions and outcomes Participants will be randomized 1:1 to a lower (3 mg) or higher (6 mg) nicotine concentration arm. Within each arm, participants will complete five laboratory sessions in balanced, randomized order: four standardized ONP sessions (30 minutes, with the pouch placed between lip and gum) varying by nicotine form (30% vs. 70% freebase) and stereoisomer ratio (racemic [50% R- and 50% S-nicotine] vs. > 99% S-nicotine), plus one session using their usual tobacco product. Sessions will be separated by at least 48 hours. The primary outcome is maximum plasma nicotine concentration (Cmax). Secondary outcomes include time to maximum concentration (Tmax), total nicotine absorbed over 90 minutes (AUC), subjective effects, and behavioral economic demand indices. Conclusions This will be the first study to systematically examine how nicotine concentration, form, and stereoisomer ratio interact to influence ONP abuse liability. Findings will identify which product characteristics drive ONP addiction potential and will inform FDA regulation aimed at maximizing the potential for ONPs to serve as a harm reduction alternative to cigarettes and moist snuff. Trial registration ClinicalTrials.gov NCT06315881 ; registered February 14, 2024.
No takes yet. Share an insight, caveat, or question.
Tomko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: